ChemoCentryx

ChemoCentryx, Inc. (NASDAQ: CCXI) is a biopharmaceutical company founded in 1997 commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. In the United States, ChemoCentryx markets TAVNEOS (avacopan), the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa (HS) and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other...

Biopharmaceutical,autoimmune diseases,inflammatory disorders,orphan and rare diseases,anca-associated vasculitis,oral therapeutics,immuno-oncology,hidradenitis suppurativa,chronic kidney disease,diabetic nephropathy,pancreatic cancer,c3 glomerulopathy,small molecule therapeutics,chemoattractant system,chemokine,drug discovery,inflammatory bowel disease (ibd),rheumatoid arthritis (ra),avacopan,complement receptor,advocate,aurora,lumina,and tavneos

Chemocentryx operates in the Biotechnology research industry.

Chemocentryx's revenue is 11m - 100m

Chemocentryx has 51 - 200 employees.